Table 2.

Rate (number responding/total treated) of patients with negative viremia during the course of the trial

	Screening	T4	T8	T12	T18	T24	T48
r-hIFN β-1a	0	18	16	21	16	15	11
(n = 51)	0%	-35.30%	-31.40%	-41.20%	-31.40%	-29.40%	-21.56%
r-hIFN β-1a + ribavirin	0	13	22	24	21	21	14
(n = 51)	0%	-25.50%	-43.10%	-47.10%	-41.20%	-41.20%	-27.45%